WO2010013762A1 - メタスチン誘導体およびその用途 - Google Patents

メタスチン誘導体およびその用途 Download PDF

Info

Publication number
WO2010013762A1
WO2010013762A1 PCT/JP2009/063533 JP2009063533W WO2010013762A1 WO 2010013762 A1 WO2010013762 A1 WO 2010013762A1 JP 2009063533 W JP2009063533 W JP 2009063533W WO 2010013762 A1 WO2010013762 A1 WO 2010013762A1
Authority
WO
WIPO (PCT)
Prior art keywords
inhibiting activity
activity
metastin derivative
metastin
cancer
Prior art date
Application number
PCT/JP2009/063533
Other languages
English (en)
French (fr)
Inventor
泰司 浅見
Original Assignee
武田薬品工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 武田薬品工業株式会社 filed Critical 武田薬品工業株式会社
Priority to JP2010522744A priority Critical patent/JP5698977B2/ja
Priority to LTEP09803004.2T priority patent/LT2314609T/lt
Priority to DK09803004.2T priority patent/DK2314609T3/en
Priority to ES09803004.2T priority patent/ES2617657T3/es
Priority to US13/056,297 priority patent/US20110212890A1/en
Priority to SI200931623A priority patent/SI2314609T1/sl
Priority to EP09803004.2A priority patent/EP2314609B1/en
Publication of WO2010013762A1 publication Critical patent/WO2010013762A1/ja
Priority to HRP20170319TT priority patent/HRP20170319T1/hr
Priority to CY20171100265T priority patent/CY1118975T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　本発明は、優れた生物活性（癌転移抑制活性、癌増殖抑制活性、性腺刺激ホルモン分泌促進活性、性ホルモン分泌促進活性等）を有する安定なメタスチン誘導体を提供する。本発明のメタスチン誘導体は、メタスチンの構成アミノ酸を置換したメタスチン誘導体とポリエチレングリコールと結合することにより、血中安定性が向上し、優れた癌転移抑制活性や癌増殖抑制活性、性腺刺激ホルモン分泌抑制作用、性ホルモン分泌抑制作用等を有する。
PCT/JP2009/063533 2008-07-30 2009-07-29 メタスチン誘導体およびその用途 WO2010013762A1 (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2010522744A JP5698977B2 (ja) 2008-07-30 2009-07-29 メタスチン誘導体およびその用途
LTEP09803004.2T LT2314609T (lt) 2008-07-30 2009-07-29 Metastino darinys ir jo panaudojimas
DK09803004.2T DK2314609T3 (en) 2008-07-30 2009-07-29 METASTIN DERIVATIVES AND USE THEREOF
ES09803004.2T ES2617657T3 (es) 2008-07-30 2009-07-29 Derivado de metastina y uso del mismo
US13/056,297 US20110212890A1 (en) 2008-07-30 2009-07-29 Metastin derivative and use thereof
SI200931623A SI2314609T1 (sl) 2008-07-30 2009-07-29 Derivat metastina in njegova uporaba
EP09803004.2A EP2314609B1 (en) 2008-07-30 2009-07-29 Metastin derivative and use thereof
HRP20170319TT HRP20170319T1 (hr) 2008-07-30 2017-02-27 Derivat metastina i njegova uporaba
CY20171100265T CY1118975T1 (el) 2008-07-30 2017-02-28 Παραγωγο μεταστινης και χρηση αυτου

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008-196598 2008-07-30
JP2008196598 2008-07-30

Publications (1)

Publication Number Publication Date
WO2010013762A1 true WO2010013762A1 (ja) 2010-02-04

Family

ID=41610461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/063533 WO2010013762A1 (ja) 2008-07-30 2009-07-29 メタスチン誘導体およびその用途

Country Status (13)

Country Link
US (1) US20110212890A1 (ja)
EP (2) EP3210998A1 (ja)
JP (1) JP5698977B2 (ja)
CY (1) CY1118975T1 (ja)
DK (1) DK2314609T3 (ja)
ES (1) ES2617657T3 (ja)
HR (1) HRP20170319T1 (ja)
HU (1) HUE030900T2 (ja)
LT (1) LT2314609T (ja)
PL (1) PL2314609T3 (ja)
PT (1) PT2314609T (ja)
SI (1) SI2314609T1 (ja)
WO (1) WO2010013762A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013017631A1 (en) 2011-08-04 2013-02-07 Msd Oss B.V. Kisspeptide-pentasaccharide conjugates
US8610095B2 (en) 2009-01-29 2013-12-17 Gigaphoton Inc. Extreme ultraviolet light source device
US11013780B2 (en) 2016-09-30 2021-05-25 Myovant Sciences Gmbh Methods of treating female infertility

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009139298A1 (ja) * 2008-04-30 2009-11-19 国立大学法人京都大学 メタスチン誘導体およびその用途

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343898A (en) 1980-02-11 1982-08-10 Novo Industri A/S Process for preparing esters of human insulin
WO1996011953A1 (en) * 1994-10-12 1996-04-25 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO2000024890A1 (fr) 1998-10-27 2000-05-04 Takeda Chemical Industries, Ltd. Nouvellesroteines receptrices couplees aux proteines g, leurs adn et leursigands
WO2001041812A2 (en) * 1999-12-13 2001-06-14 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
WO2001075104A1 (fr) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Nouvelle proteine, adn codant pour celle-ci, et son procede de production
WO2002085399A1 (en) 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Peptide-containing preparations
WO2004060264A2 (en) 2003-01-06 2004-07-22 Takeda Pharmaceutical Company Limited Metastin derivatives and their use
WO2004063221A1 (ja) 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited メタスチン誘導体およびその用途
WO2006001499A2 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
WO2007072997A1 (en) 2005-12-22 2007-06-28 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
WO2007109135A2 (en) * 2006-03-20 2007-09-27 Merck & Co., Inc. Neuromedin u receptor agonists and uses thereof
WO2007125619A1 (ja) 2006-04-26 2007-11-08 Kyoto University Ｇｐｒ５４アゴニスト活性を有する新規化合物
WO2008050897A1 (en) 2006-10-25 2008-05-02 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JP2008114480A (ja) 2006-11-06 2008-05-22 Bridgestone Corp タイヤ加硫モールドの洗浄方法および装置
JP2009058102A (ja) 2007-09-03 2009-03-19 Akebono Brake Ind Co Ltd パッドクリップ及び多板ディスクブレーキ

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838259B2 (en) * 1999-12-17 2005-01-04 Takeda Chemical Industries, Ltd. Process for producing kiss-1 peptide
US7112662B2 (en) * 2001-09-19 2006-09-26 Takeda Pharmaceutical Company Limited Anti-metasin antibodies and their methods of use
CA2472423A1 (en) * 2002-01-11 2003-07-24 Takeda Chemical Industries, Ltd. Process for producing kiss-1 peptide
AU2003272964A1 (en) * 2002-10-09 2004-05-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for hormone-dependent cancer
JP4804714B2 (ja) * 2002-12-26 2011-11-02 武田薬品工業株式会社 メタスチン誘導体およびその用途
EP1604682A4 (en) * 2003-03-12 2009-06-24 Takeda Chemical Industries Ltd AGENTS IMPROVING GONADIC FUNCTION
EP1750513A4 (en) * 2004-04-23 2009-07-22 Serono Lab USE OF GPCR54 LIGANDS FOR THE TREATMENT OF INFERTILITY
WO2007084211A2 (en) * 2005-11-11 2007-07-26 The General Hospital Corporation Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception
US20090099334A1 (en) * 2005-12-22 2009-04-16 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090093615A1 (en) * 2005-12-22 2009-04-09 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
WO2007109857A1 (en) * 2006-03-28 2007-10-04 Biopharmica Ltd Agent for the treatment of hormone-dependent disorders and uses thereof
JPWO2009044918A1 (ja) * 2007-10-05 2011-02-17 武田薬品工業株式会社 ニューロメジンｕ誘導体

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343898A (en) 1980-02-11 1982-08-10 Novo Industri A/S Process for preparing esters of human insulin
WO1996011953A1 (en) * 1994-10-12 1996-04-25 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO2000024890A1 (fr) 1998-10-27 2000-05-04 Takeda Chemical Industries, Ltd. Nouvellesroteines receptrices couplees aux proteines g, leurs adn et leursigands
WO2001041812A2 (en) * 1999-12-13 2001-06-14 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
WO2001075104A1 (fr) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Nouvelle proteine, adn codant pour celle-ci, et son procede de production
WO2002085399A1 (en) 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Peptide-containing preparations
WO2004063221A1 (ja) 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited メタスチン誘導体およびその用途
WO2004060264A2 (en) 2003-01-06 2004-07-22 Takeda Pharmaceutical Company Limited Metastin derivatives and their use
WO2006001499A2 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
WO2007072997A1 (en) 2005-12-22 2007-06-28 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
WO2007109135A2 (en) * 2006-03-20 2007-09-27 Merck & Co., Inc. Neuromedin u receptor agonists and uses thereof
WO2007125619A1 (ja) 2006-04-26 2007-11-08 Kyoto University Ｇｐｒ５４アゴニスト活性を有する新規化合物
WO2008050897A1 (en) 2006-10-25 2008-05-02 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JP2008114480A (ja) 2006-11-06 2008-05-22 Bridgestone Corp タイヤ加硫モールドの洗浄方法および装置
JP2009058102A (ja) 2007-09-03 2009-03-19 Akebono Brake Ind Co Ltd パッドクリップ及び多板ディスクブレーキ

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Bunshisekkei", vol. 7, 1990, HIROKAWA PUBLISHING CO., article "Iyakuhin no Kaihatsu", pages: 163 - 198
"Haruaki Yajima & Shunpei Sakakibara: Seikagaku Jikken Koza", TANPAKUSHITSU NO KAGAKU, vol. IV, 1977, pages 205
"Peptide Synthesis", vol. 14, HIROKAWA SHOTEN, article "Zoku Iyakuhin no Kaihatsu"
INTERNATIONAL JOURNAL OF PEPTIDE & PROTEIN RESEARCH, vol. 43, 1994, pages 127 - 138
J. SAMBROOK ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOR LAB. PRESS
M. BODANSZKY; M.A. ONDETTI: "Peptide Synthesis", 1966, INTERSCIENCE PUBLISHERS
NOBUO IZUMIYA ET AL.: "Peptide Gosei-no-Kiso to Jikken", 1975, MARUZEN CO.
ROBERTS, M. ET AL., ADVANCED DRUG DELIVERY REVIEWS, vol. 54, 2002, pages 457 - 476
SCHROEDER; LUEBKE: "The Peptide", 1965, ACADEMIC PRESS
See also references of EP2314609A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8610095B2 (en) 2009-01-29 2013-12-17 Gigaphoton Inc. Extreme ultraviolet light source device
WO2013017631A1 (en) 2011-08-04 2013-02-07 Msd Oss B.V. Kisspeptide-pentasaccharide conjugates
US9127038B2 (en) 2011-08-04 2015-09-08 Merck Sharp & Dohme Corp. Kisspeptide-pentasaccharide conjugates
US11013780B2 (en) 2016-09-30 2021-05-25 Myovant Sciences Gmbh Methods of treating female infertility
US11638740B2 (en) 2016-09-30 2023-05-02 Myovant Sciences Gmbh Methods of treating female infertility

Also Published As

Publication number Publication date
EP2314609B1 (en) 2016-11-30
HUE030900T2 (en) 2017-06-28
JPWO2010013762A1 (ja) 2012-01-12
EP2314609A1 (en) 2011-04-27
EP2314609A4 (en) 2013-01-16
LT2314609T (lt) 2017-04-10
CY1118975T1 (el) 2018-01-10
ES2617657T3 (es) 2017-06-19
US20110212890A1 (en) 2011-09-01
PL2314609T3 (pl) 2017-07-31
EP3210998A1 (en) 2017-08-30
DK2314609T3 (en) 2017-03-13
SI2314609T1 (sl) 2017-05-31
HRP20170319T1 (hr) 2017-05-05
JP5698977B2 (ja) 2015-04-08
PT2314609T (pt) 2017-03-06

Similar Documents

Publication Publication Date Title
WO2008150485A3 (en) Erbb2 binding proteins and use thereof
MY145975A (en) Metastin derivatives and use thereof
IL244812A0 (en) 6-ethyl, 23-methyl-cholic acid, its conjugates with glycine and taurine and pharmaceutical preparations containing them
IL215603A0 (en) Human protein scaffold with controlled serum pharmacokinetics, compositions comprising the same and uses thereof
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
EP2921177A3 (en) Dual variable domain immunoglobulins and uses thereof
MY151967A (en) Metastin derivatives and use thereof
WO2007143098A8 (en) Hepatocyte growth factor (hgf) binding proteins
WO2011104381A3 (en) Stable antibody containing compositions
WO2012012682A3 (en) Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
ZA201100704B (en) Production,formulation,and uses of stable liquid harpin protein formulations
LT1986981T (lt) Preparatai su pagerintomis ureazę slopinančiomis savybėmis ir šie preparatai, turintys karbamido pagrindo trąšų
WO2008058239A3 (en) Spink1 as a prostate cancer marker and uses thereof
WO2008079973A3 (en) Egfr binding peptides and uses thereof
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
WO2008089397A3 (en) Adrb2 cancer markers
PL2586319T3 (pl) Kompozycja zawierająca substancję smakowo-zapachową i kwas organiczny oraz jej zastosowanie
WO2009055074A8 (en) Erbb2 binding proteins and use thereof
MX2010007716A (es) Combinacion de una proteina de fusion del anticuerpo-il-2 de anti-edb fibronectina y una molecula que se une a celulas b, progenitores de la celula b y/o sus contrapartes cancerigenas.
WO2010025370A3 (en) Preparation of ranolazine
WO2010013762A1 (ja) メタスチン誘導体およびその用途
EP2270145A4 (en) NEW HYALURONIC ACID BINDING PROTEIN AND METHOD FOR MEASURING HYALURONIC ACID THEREFOR
WO2009030065A8 (zh) 聚乙二醇修饰的干扰素α2a及其制备方法和应用
WO2009047634A3 (en) Aqueous formulations of acetaminophen for injection
GB2488493B (en) Sunless tanning compositon comprising dihydroxyacetone and pyranones

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09803004

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010522744

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 13056297

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2009803004

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009803004

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE